All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumab

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F14%3A10283728" target="_blank" >RIV/00179906:_____/14:10283728 - isvavai.cz</a>

  • Alternative codes found

    RIV/00216208:11150/14:10283728

  • Result on the web

    <a href="http://www.dovepress.com/targeted-treatment-for-chronic-lymphocytic-leukemia-clinical-potential-peer-reviewed-article-PGPM" target="_blank" >http://www.dovepress.com/targeted-treatment-for-chronic-lymphocytic-leukemia-clinical-potential-peer-reviewed-article-PGPM</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.2147/PGPM.S55501" target="_blank" >10.2147/PGPM.S55501</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumab

  • Original language description

    Introduction of targeted agents revolutionized the treatment of chronic lymphocytic leukemia (CLL) in the past decade. Addition of chimeric monoclonal anti-CD20 antibody rituximab to chemotherapy significantly improved efficacy including overall survival(OS) in untreated fit patients; humanized anti-CD52 antibody alemtuzumab and fully human anti-CD20 antibody ofatumumab lead to improvement in refractory disease. Novel small molecule inhibitors such as ibrutinib and idelalisib demonstrated excellent activity and were very recently licensed in relapsed/refractory CLL. Obinutuzumab (GA101) is the newest monoclonal antibody approved for the treatment of CLL. This novel, glycoengineered, type II humanized anti-CD20 antibody is characterized by enhanced antibody-dependent cellular cytotoxicity and direct induction of cell death compared to type I antibodies. Combination of obinutuzumab and chlorambucil yielded significantly better OS in comparison to chlorambucil monotherapy in untreated co

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

  • CEP classification

    FD - Oncology and haematology

  • OECD FORD branch

Result continuities

  • Project

    <a href="/en/project/NT13412" target="_blank" >NT13412: Complex assessment of microenvironment and its impact on clinical course of chronic lymphocytic leukemia.</a><br>

  • Continuities

    P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Others

  • Publication year

    2014

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Pharmacogenomics and Personalized Medicine

  • ISSN

    1178-7066

  • e-ISSN

  • Volume of the periodical

    8

  • Issue of the periodical within the volume

    2014

  • Country of publishing house

    GB - UNITED KINGDOM

  • Number of pages

    7

  • Pages from-to

    1-7

  • UT code for WoS article

  • EID of the result in the Scopus database